ArticleFrontiers in neurology
Effects and central mechanisms of acupuncture for post-stroke vascular vertigo: study protocol of a multicenter, randomized, sham-controlled trial.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vascular vertigo is a common sequela following stroke, significantly impairing patients' quality of life and rehabilitation progress. Although Western pharmaceutical treatments are widely used, their long-term efficacy is limited and associated with side effects. Acupuncture, a traditional Chinese medical therapy, has potential advantages in alleviating vertigo symptoms. This study aims to evaluate the efficacy and central mechanisms of acupuncture for post-stroke vascular vertigo (PSVV). Methods: This study is a multicenter, double-blind, randomized controlled trial planned to enroll 234 patients with PSVV from four subcenters. Participants will be randomly assigned in a 1:1:1 ratio to the acupuncture group, the sham acupuncture group, or the active drug group. The trial comprises a 1-week induction period, a 3-week treatment period, and follow-up periods at 8 weeks and 20 weeks. Following the induction period, the drug group will receive betahistine mesilate tablets orally, the acupuncture group will receive needling at Baihui (GV20), Fengchi (GB20), Wangu (GB12), and Taichong (LR3), and the sham acupuncture group will receive superficial needling at non-acupoints combined with blunt needle. All groups will undergo intervention 3 weeks. The primary outcome will be the Dizziness Handicap Inventory (DHI), with secondary outcomes including the Dizziness and Anxiety Rating Scale (DARS), dizziness diaries, the 36-Item Short Form Health Survey (SF-36), transcranial Doppler ultrasonography (TCD), multimodal magnetic resonance imaging (MRI), and Expectation Rating Scale (ERS). The relationship between clinical efficacy and the mechanisms of the prescribed interventions will be explored. Treatment safety will be assessed through adverse event records. Discussion: This trial will be the first to compare the efficacy of acupuncture, sham acupuncture, and Western medication in treating PSVV. It aims to demonstrate whether acupuncture is safe and effective for this condition and to elucidate its central nervous system mechanisms. We anticipate that this research will provide clinical evidence for the management of PSVV. Ethics and dissemination: The Medical Ethics Committee of the Chengdu University of Traditional Chinese Medicine Affiliated Hospital has given study approval (approval no. 2025KL-062). The findings will be disseminated through publications, conferences, and briefs to professional organizations. Clinical trial registration: http://itmctr.ccebtcm.org.cn, identifier ITMCTR2025001283.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.